Literature DB >> 14998186

Blastocyst versus early cleavage embryo transfer: a retrospective analysis of 4,165 transfers.

K Pantos1, E Makrakis, P Karantzis, D Stavrou, M Grammatis, K Chronopoulos.   

Abstract

PURPOSE: To compare the clinical outcomes after the transfer of blastocysts versus early cleavage embryos in assisted reproduction technologies (ART).
METHODS: A retrospective analysis of all the ovarian stimulation-in vitro fertilization-embryo transfer cycles performed at the Centre for Human Reproduction, Athens, Greece, between June 1997 and December 2001.
RESULTS: The number of blastocysts transferred per ET was significantly lower compared to that of all early cleavage embryos. The implantation rate of blastocysts was significantly higher compared to that of all other modes of transfer. Clinical pregnancy rate after the transfer of blastocysts was significantly increased compared to that after transfer of any early cleavage embryo. The viable pregnancy rate after the transfer of blastocysts was significantly increased only compared to that after the transfer of day-2 embryos. There were no significant differences regarding the multiple gestation rates among the various modes of transfer.
CONCLUSION: The use of blastocysts in ART is beneficial when compared to that of day-2 embryos and at least comparable to that of day-3 embryos. Blastocyst culture and transfer remains a favourable and promising option in ART.

Entities:  

Mesh:

Year:  2004        PMID: 14998186

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  2 in total

1.  Blastocyst stage transfer vs cleavage stage embryo transfer.

Authors:  Ann M Mangalraj; K Muthukumar; Tk Aleyamma; Mohan S Kamath; Korula George
Journal:  J Hum Reprod Sci       Date:  2009-01

2.  Abnormal Elevation of Anti-Mullerian Hormone and Androgen Levels Presenting as Granulosa Cell Tumor.

Authors:  Hongbin Chi; Ning Huang; Huamao Liang; Rong Li; Congrong Liu; Jie Qiao
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.